Using advanced MRI to identify high-risk areas in brain tumors for radiation planning
Official title: Using Advanced MR Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans: A Pilot Study, and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
Run by Memorial Sloan Kettering Cancer Center · NCT00870129 · Data updated 2026-11-12
This study is testing if advanced MRI can help doctors find the most dangerous parts of brain tumors to plan better radiation treatment for patients with malignant gliomas.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 135 (estimated) |
| Sponsor | Memorial Sloan Kettering Cancer Center Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (New York, New York) |
| Status | Recruiting |
| Started | March 2009 |
| Main results expected | September 2027 |
| Study ends | September 2027 |
| Registry record updated | October 14, 2026 |
| Trial ID | NCT00870129 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with a suspected or confirmed diagnosis of high-grade or low-grade glioma, particularly those with an isocitrate dehydrogenase (IDH) mutation.
✕Probably not a fit
Patients with extreme claustrophobia, known allergies to MRI contrast agents, or any contraindications to MRI or radiation therapy will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the use of advanced magnetic resonance imaging (MRI) techniques to identify high-risk areas within malignant gliomas, which are aggressive brain tumors. The goal is to determine if this imaging approach can enhance the planning of radiation therapy and assess changes in metabolites associated with gliomas and other solid tumors. Researchers aim to evaluate the safety and tolerability of these advanced imaging methods in patients with brain tumors. By improving the precision of radiation treatment, the study seeks to optimize patient outcomes.
Why it matters
Potential benefit: If successful, this approach could lead to more effective radiation therapy plans for patients with malignant gliomas, potentially improving survival rates and quality of life.
How similar studies have gone: Other studies utilizing advanced MRI techniques for tumor characterization and treatment planning have shown promising results, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Suspected or Histopathologically proven diagnosis of high grade or low glioma or tumor is suspected to harbor an isocitrate dehydrogenase (IDH) mutation * May undergo radiation therapy * Patient and/or guardian is able to provide written informed consent prior to study registration * Age ≥ 18 years old Exclusion Criteria: * Extreme claustrophobia that precludes MRI scan * Known allergic reaction to Gd-DTPA * Any contraindication to gadolinium intravenous contrast as per standard Department of Radiology contrast guidelines * Any absolute contraindication to MRI (e.g., pacemaker, aneurysm clip, tissue expander). * Pregnant or nursing female * Unable to cooperate for MRI and/or radiation therapy planning
Where it's running
-
Memorial Sloan Kettering Cancer Center
New York, New York, United States Recruiting
Study contacts
- Principal investigator: Robert Young, MD — Memorial Sloan Kettering Cancer Center
- Study coordinator: Robert Young, MD
- Phone: 212-639-8196
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
LMP744 (an indenoisoquinolone) for people with recurrent glioblastoma
This trial will test whether the drug LMP744 can shrink tumors or slow progression in adults whose glioblastoma has returned after prior treatment.
-
Silevertinib plus temozolomide for newly diagnosed GBM with unmethylated MGMT and EGFRvIII
This trial tests whether adding silevertinib to standard temozolomide helps people with newly diagnosed glioblastoma that have EGFRvIII and an unmethylated MGMT promoter live longer without the cancer getting worse.
-
Fluorescent-labeled nivolumab (Nivo800) imaging for high-grade glioma surgery
This trial tests whether a near-infrared fluorescent version of the immunotherapy drug nivolumab can be given before planned surgery to visualize drug distribution in adults with suspected high-grade glioma.
-
Combining TIL Therapy and Pembrolizumab for Advanced Brain Cancer
This study is testing a new treatment that combines a type of immune therapy using patients' own tumor cells with Pembrolizumab to see if it helps people with advanced brain cancer feel better and live longer.
-
Using omental tissue to treat recurrent glioblastoma
This study is testing whether using a piece of fat from the abdomen can help improve treatment for patients with recurrent glioblastoma by delivering medication and immune cells more effectively to the tumor site.
-
Gene therapy combined with radiotherapy for brain tumors
This study is testing a new gene therapy combined with targeted radiation to see if it can safely help people with recurrent high-grade brain tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.